University of California San Francisco
Give to UCSF
Action Plans Set in Response to UCSF 2023 Staff Engagement Survey
UCSF’s engagement survey results were revealed in late June. This article will recap those results, highlight key items in the findings and any action steps UCSF is taking.
Oakland Hospital First in West to Pioneer Beta Thalassemia Drug
UCSF Benioff Children’s Hospital Oakland is the first hospital in the West to administer a newly approved gene therapy to treat beta thalassemia with gene therapy, reducing the need for lifelong blood transfusions.
Gene Editing of Microbiome May Help Prevent Asthma in Children
Could the microbes in our guts be a treatment for asthma? UCSF scientists are working to find out.
Can an Artificial Kidney Finally Free Patients from Dialysis?
Scientist proved for the first time that kidney cells, housed in an implantable device functioning as an artificial kidney, can survive inside the body of an animal.
UCSF’s Chase Anderson Leverages His ‘Superpower’ for a Better Future
UCSF’s Chase Anderson shares his story of intersectional identities and depression, and how his experiences shape his role as a child psychiatrist.
UCSF Legal Taps Nosowsky as Health System’s First Chief Counsel
UCSF has appointed Rachel Nosowsky as the first chief counsel for UCSF Health to advise and guide the expanding enterprise and lead a team of attorneys in support of Health priorities.
How Artificial Intelligence Gave a Paralyzed Woman Her Voice Back
A brain implant and digital avatar allow a paralyzed stroke survivor to speak with for first time in 18 years with the help of artificial intelligence.
How to BEST Manage Mental Health and Pain of a Long-term Diagnosis?
Manvir, a young cancer patient, worked with the UCSF Benioff Oakland Braddock Emotional Support Team (BEST) to alleviate his emotional and physical pain from his treatments. A new gift will help expand BEST behavioral and mental health services to young cancer patients and their families.
How to Stop Dangerous Scarring After a Heart Attack
Gal-3C, a galectin-3 inhibitor, shows promise in limiting post-MI scarring, improving cardiac function, and outperforming current therapies.
